Skip to content

Efficacy and safety of Vernonia cinerea for smoking cessation

Efficacy and safety of Vernonia cinerea for smoking cessation: an open-label randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20190506002
Enrollment
Unknown
Registered
2019-05-06
Start date
2019-01-07
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking cessation Safety of long term used of Vernonia cinerea Vernonia cinerea nortriptyline tobacco dependence smoking cessation safety

Interventions

Participants in intervention group received a 2 gram of Vernonia cinerea tea bag premeal three times daily by pouring 150 mL boiling water over tea bag&#44
stirring well&#44
covering cup for 15 minutes before drinking for 12 weeks. ,nortriptyline started at 25 mg before bed once daily for days 1 through 3&#44
followed by 50 mg once daily for days 3 through 7&#44
and then 75 mg once daily for days 8 through 28 for reduced potential adverse events.
Experimental Drug,Active Comparator Drug
Vernonia cinerea ,nortriptyline

Sponsors

Namphong Hospital
Lead Sponsor
Khon Kaen Hospital
Collaborator

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Adults with smoking dependence were screened for participation in the study. Inclusion criteria included moderate to severe nicotine dependence (Heaviness of smoking index, HSI) ≥3 at least 1 month before randomization

Exclusion criteria

Exclusion criteria: Patients with a history of either Vernonia cinerea or nortriptyline allergy, comorbidities (heart disease, cancer, urinary retention, benign prostatic hyperplasia, glaucoma, abnormal vision, dry mouth, constipation, history of gut obstruction, abnormal function of either liver or kidney, abnormal serum potassium level, neurological disorder, depression, used other types of tobacco, used other substances), pregnancy, on breastfeeding period, used MAOIs drug at least 14 days before randomization, used drugs that may cause drug interactions with nortriptyline and used other drugs for smoking cessation were excluded.

Design outcomes

Primary

MeasureTime frame
continuous abstinence rate 12 weeks self-report, direct observe treatment, exhaled carbon monoxide level

Secondary

MeasureTime frame
continuous abstinence rate 2, 4, 8, 24 weeks self-report, direct observe treatment, exhaled carbon monoxide level,amount of cigarette per day 2, 4, 8, 12, 24 weeks self-report, direct observe treatment,exhaled carbon monoxide level 2, 4, 8, 12, 24 weeks ีSmokerlyzer device (-ppm),adverse events 2, 4, 8, 12, 24 weeks self-report, direct observe treatment,withdrawal symptoms. 2, 4, 8, 12, 24 weeks self-report, direct observe treatment

Countries

Thailand

Contacts

Public ContactKrissanaporn Tuenthosarn

Khon Kaen Hospital Institute Review Board in Human Research.

K.tuenthosarn@gmail.com0878638776

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026